Regulatory Overhaul: How the NMPA's Reforms are Catalyzing Foreign Investment in the China Biologics Sector
The historical challenge for foreign pharmaceutical companies entering the **China Biologics Market** was often rooted in a lengthy and opaque regulatory process, characterized by significant delays compared to the FDA or EMA. This environment has been dramatically altered by a sweeping regulatory overhaul led by the National Medical Products Administration (NMPA) since the mid-2010s. These...
0 Комментарии 0 Поделились 310 Просмотры 0 предпросмотр
MTSocial https://mtsocial.ir